Fig. 1: Cell free DNA (cfDNA) yield and circulating tumor DNA (ctDNA) fraction in A031201 plasma specimens. | Nature Communications

Fig. 1: Cell free DNA (cfDNA) yield and circulating tumor DNA (ctDNA) fraction in A031201 plasma specimens.

From: AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients

Fig. 1

a CONSORT flow diagram of patients enrolled in A031201 and plasma cfDNA specimens analyzed by targeted DNA-seq. ‘n’ refers to the number of patients. b AR-ctDETECT targeted DNA-seq assay design. c Scatterplot of ctDNA aneuploidy fraction estimated by ichorCNA using off-target DNA-seq reads vs. cfDNA yield from 776 plasma specimens analyzed by targeted DNA-seq. Loess trendline and 95% confidence intervals are shown. Violin plots illustrate data density from min to max. Boxes in violin plots illustrate median and interquartile range. Whiskers illustrate 1.5X interquartile range. d ctDNA aneuploidy fraction estimate as in (c) using cfDNA isolated from pooled plasma from healthy donors. Violin plots illustrate data density from min to max. Boxes in violin plots illustrate median and interquartile range. Whiskers illustrate 1.5X interquartile range. An assay cutoff of mean + 3 standard deviations (0.142) distinguishes ctDNA aneuploidy-high specimens.

Back to article page